MRI scan for detecting pancreatic cancer in people at high risk

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop and evaluate a specialized MRI protocol for imaging the pancreas in individuals at elevated risk for pancreatic cancer. Participants may also undergo endoscopic ultrasound as part of assessments. The study focuses on identifying imaging features that could enable earlier detection in high-risk populations. Enrollment is limited to US residents who meet specific genetic and familial criteria and who have no actionable pancreatic findings on prior imaging. No intervention beyond imaging procedures is described in the available materials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual
* Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer
* Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2
* Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+

For this pilot MRP study, we will additionally apply the following Criteria:

* Consents to follow-up contact
* US residents
* Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass)
* No metallic artifacts covering the pancreas on prior MRCP
* Scheduled for endoscopic ultrasound
* No new contraindications for MRI (e.g. new MR unsafe device)
* No history of claustrophobia or use of anxiolytic on prior MRI
* No history of abdominal surgery that may affect interpretation of either EUS or MR
* No medical conditions that confers increased and/or unacceptable risk for anesthesia

We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in \~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget.

* Documentation of Disease

  o No pathologic confirmation of disease is necessary
* Definition of Disease N/A
* Required Organ Function N/A

Exclusion Criteria:

\-

Where it's running

• Memorial Sloan Kettering Basking Ridge (Consent Only)
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth (Consent only)
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen (Consent Only)
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Suffolk-Commack (Consent only)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester (Consent only)
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center (All Protocol Activites)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Richard Kinh Gian Do, MD, PhD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Richard Kinh Gian Do, MD, PhD
• Email: dok@mskcc.org
• Phone: 212-639-8591

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining SBRT with defactinib and avutometinib for advanced pancreatic cancer

  This Phase 2 trial tests whether adding the targeted drugs defactinib and avutometinib to adaptive SBRT helps people with locally advanced or borderline resectable pancreatic cancer stay progression-free longer than SBRT alone.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07126158

• Treatment for advanced pancreatic cancer using engineered immune cells

  This study is testing a new treatment that uses specially modified immune cells to see if it can help people with advanced pancreatic cancer feel better and fight their disease.

  Recruiting Phase 1/2 University of Virginia · Charlottesville, Virginia · NCT06479239

• Using the HistoSonics Edison System to treat pancreatic cancer

  This study is testing a new treatment using the HistoSonics Edison System to see if it can safely destroy tumors in patients with advanced pancreatic cancer that can't be removed by surgery.

  Recruiting HistoSonics, Inc. · Barcelona · NCT06282809

• Assessing the effects of radiotherapy on tumors in cervical and pancreatic cancer

  This study is testing how radiotherapy affects tumors in patients with locally advanced cervical and pancreatic cancer by collecting samples and using special imaging before, during, and after treatment.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT05975593

• Combining surufatinib and camrelizumab with chemotherapy for advanced pancreatic cancer

  This study is testing a new combination of treatments for people with advanced pancreatic cancer to see if it works better than the standard options.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing · NCT05218889

• Analyzing solid tumors for HLA loss and collecting T cells for CAR T-cell therapy

  This study is testing how often solid tumors lose a key protein that helps the immune system recognize them, while also collecting T cells from patients with high-risk cancers to prepare for future CAR T-cell therapy.

  Recruiting at 13 sites A2 Biotherapeutics Inc. · Gilbert, Arizona and 15 other locations · NCT04981119

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.